Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQT NASDAQ:CMPS NASDAQ:ETNB NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$19.76-0.8%$16.54$8.03▼$21.30$2.39B2.062.01 million shs2.15 million shsCMPSCOMPASS Pathways$6.29-2.2%$4.82$2.25▼$6.63$616.90M2.211.56 million shs2.19 million shsETNB89BIO$14.87+0.1%$10.40$4.16▼$15.06$2.20B1.279.40 million shs1.75 million shsOCULOcular Therapeutix$10.97-3.9%$12.28$5.78▼$13.85$1.99B1.453.21 million shs3.66 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%+13.38%+16.15%+48.77%+98.80%CMPSCOMPASS Pathways0.00%+10.86%+25.10%+94.26%+3.54%ETNB89BIO0.00%+1.02%+67.42%+45.30%+106.54%OCULOcular Therapeutix0.00%-8.94%-16.10%+18.73%+15.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$19.76-0.8%$16.54$8.03▼$21.30$2.39B2.062.01 million shs2.15 million shsCMPSCOMPASS Pathways$6.29-2.2%$4.82$2.25▼$6.63$616.90M2.211.56 million shs2.19 million shsETNB89BIO$14.87+0.1%$10.40$4.16▼$15.06$2.20B1.279.40 million shs1.75 million shsOCULOcular Therapeutix$10.97-3.9%$12.28$5.78▼$13.85$1.99B1.453.21 million shs3.66 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%+13.38%+16.15%+48.77%+98.80%CMPSCOMPASS Pathways0.00%+10.86%+25.10%+94.26%+3.54%ETNB89BIO0.00%+1.02%+67.42%+45.30%+106.54%OCULOcular Therapeutix0.00%-8.94%-16.10%+18.73%+15.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.63Moderate Buy$19.800.20% UpsideCMPSCOMPASS Pathways 2.63Moderate Buy$16.29158.91% UpsideETNB89BIO 2.40Hold$25.8173.59% UpsideOCULOcular Therapeutix 2.75Moderate Buy$22.13101.69% UpsideCurrent Analyst Ratings BreakdownLatest CMPS, ARQT, ETNB, and OCUL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/3/2025OCULOcular TherapeutixPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$21.00 ➝ $31.0010/3/2025OCULOcular TherapeutixRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$17.00 ➝ $24.0010/2/2025OCULOcular TherapeutixZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/2/2025OCULOcular TherapeutixChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.0010/1/2025OCULOcular TherapeutixCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/1/2025OCULOcular TherapeutixJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$20.00 ➝ $29.0010/1/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.009/27/2025ARQTArcutis BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CMPSCOMPASS PathwaysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025OCULOcular TherapeutixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$196.54M12.05N/AN/A$1.35 per share14.64CMPSCOMPASS PathwaysN/AN/AN/AN/A$2.26 per shareN/AETNB89BION/AN/AN/AN/A$3.34 per shareN/AOCULOcular Therapeutix$63.72M29.95N/AN/A$2.01 per share5.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$140.04M-$0.750.00N/AN/A-35.40%-62.62%-25.16%10/28/2025 (Estimated)CMPSCOMPASS Pathways-$155.12M-$1.840.00N/AN/AN/A-87.89%-57.77%10/30/2025 (Estimated)ETNB89BIO-$367.08M-$3.610.00N/AN/AN/A-94.48%-80.92%11/6/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.280.00N/AN/A-382.51%-71.92%-49.36%11/13/2025 (Estimated)Latest CMPS, ARQT, ETNB, and OCUL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025CMPSCOMPASS Pathways-$0.40N/AN/AN/AN/AN/A10/28/2025Q3 2025ARQTArcutis Biotherapeutics-$0.09N/AN/AN/A$86.69 millionN/A8/7/2025Q2 2025ETNB89BIO-$0.49-$0.71-$0.22-$0.71N/AN/A8/6/2025Q2 2025ARQTArcutis Biotherapeutics-$0.18-$0.13+$0.05-$0.13$72.70 million$81.50 million8/5/2025Q2 2025OCULOcular Therapeutix-$0.35-$0.39-$0.04-$0.39$13.12 million$13.46 million7/31/2025Q2 2025CMPSCOMPASS Pathways-$0.37-$0.38-$0.01-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.773.203.04CMPSCOMPASS Pathways0.168.828.82ETNB89BIO0.0715.1915.19OCULOcular Therapeutix0.2310.1010.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ACMPSCOMPASS Pathways46.19%ETNB89BION/AOCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%CMPSCOMPASS Pathways3.93%ETNB89BIO2.80%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.90 million108.63 millionOptionableCMPSCOMPASS Pathways12095.94 million92.17 millionOptionableETNB89BIO40148.31 million144.16 millionOptionableOCULOcular Therapeutix230173.99 million169.99 millionOptionableCMPS, ARQT, ETNB, and OCUL HeadlinesRecent News About These CompaniesOcular Therapeutix (NASDAQ:OCUL) Insider Sells $106,472.59 in Stock2 hours ago | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Insider Jeffrey Heier Sells 10,502 Shares2 hours ago | marketbeat.comBaird Maintains Ocular Therapeutix (OCUL) Outperform RecommendationOctober 5 at 11:22 PM | msn.comEquities Analysts Set Expectations for OCUL FY2025 EarningsOctober 5 at 2:05 AM | americanbankingnews.comPiper Sandler Maintains Ocular Therapeutix (OCUL) Overweight RecommendationOctober 4 at 1:16 PM | msn.comLooking at the Changing Narrative for Ocular Therapeutix After Recent Analyst UpdatesOctober 4 at 1:16 PM | finance.yahoo.comOcular Therapeutix (NASDAQ:OCUL) Stock Rating Upgraded by Zacks ResearchOctober 4 at 6:01 AM | marketbeat.comBrokerages Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) Price Target at $17.83October 4 at 3:29 AM | americanbankingnews.comOcular Therapeutix price target raised to $31 from $21 at Piper SandlerOctober 3 at 12:45 PM | msn.comOcular Therapeutix price target raised to $24 from $17 at BairdOctober 3 at 12:45 PM | msn.comWilliam Blair Has Positive Outlook of OCUL FY2025 EarningsOctober 3 at 6:50 AM | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Earns "Buy" Rating from Chardan CapitalOctober 3 at 3:03 AM | americanbankingnews.comNeedham & Company LLC Issues Positive Forecast for Ocular Therapeutix (NASDAQ:OCUL) Stock PriceOctober 3 at 2:53 AM | americanbankingnews.comOcular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan CapitalOctober 2, 2025 | marketbeat.comNeedham Maintains Ocular Therapeutix (OCUL) Buy RecommendationOctober 2, 2025 | msn.comOcular Therapeutix (OCUL) Falls Hard on $475-Million Share SaleOctober 2, 2025 | insidermonkey.comOcular Therapeutix Announces $475M Stock OfferingOctober 2, 2025 | msn.comJMP Securities Maintains Ocular Therapeutix (OCUL) Market Outperform RecommendationOctober 2, 2025 | msn.comOcular Therapeutix (OCUL) Falls Hard on $475-Million Share SaleOctober 2, 2025 | msn.com11 Stocks Failing to Keep up With The MarketOctober 1, 2025 | insidermonkey.comOcular Therapeutix price target raised to $29 from $20 at Citizens JMPOctober 1, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPS, ARQT, ETNB, and OCUL Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$19.76 -0.16 (-0.80%) Closing price 04:00 PM EasternExtended Trading$19.77 +0.01 (+0.03%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.COMPASS Pathways NASDAQ:CMPS$6.29 -0.14 (-2.18%) Closing price 04:00 PM EasternExtended Trading$6.27 -0.02 (-0.32%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.89BIO NASDAQ:ETNB$14.87 +0.02 (+0.13%) Closing price 04:00 PM EasternExtended Trading$14.80 -0.07 (-0.50%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Ocular Therapeutix NASDAQ:OCUL$10.97 -0.44 (-3.86%) Closing price 04:00 PM EasternExtended Trading$10.92 -0.05 (-0.45%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Insiders Buy Shares—Should Investors Follow Suit? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Best Stocks Under $15? 3 Low-Priced Picks With Upside After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength Broadcom’s VMware Push Takes Aim at Microsoft, Google, & Amazon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
